New 'Alpha Bullets' radiation device targets tough pancreatic tumors

NCT ID NCT06698458

First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 41 times

Summary

This study tests a new device called DaRT that delivers a special type of radiation directly into pancreatic tumors. It is being combined with standard chemotherapy in 30 people with advanced or metastatic pancreatic cancer. The main goal is to see if the combination is safe, and also to check if it helps control pain and shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Advent Health Cancer Institute

    NOT_YET_RECRUITING

    Orlando, Florida, 32804, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Banner MD Anderson Cancer Center

    RECRUITING

    Gilbert, Arizona, 85234, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

  • Bassett Healthcare Network

    RECRUITING

    Cooperstown, New York, 13326, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77054, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cedars-Sinai

    NOT_YET_RECRUITING

    Los Angeles, California, 90048, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

  • City of Hope

    NOT_YET_RECRUITING

    Goodyear, Arizona, 85338, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

  • Emory University

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact

  • Hadassah Ein Kerem

    RECRUITING

    Jerusalem, Israel

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Honor Health

    RECRUITING

    Scottsdale, Arizona, 85258, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Jewish General Hospital

    RECRUITING

    Montreal, Quebec, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Lenox hill Hospital

    NOT_YET_RECRUITING

    New York, New York, 10075, United States

    Contact Email: •••••@•••••

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10467, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Texas Oncology

    NOT_YET_RECRUITING

    Houston, Texas, 75251, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Cancer and Diagnostic

    RECRUITING

    Houston, Texas, 77089, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Diffusing Alpha Radiation Emitters Therapy (DaRT) device

What this could lead to

If it works, this could offer a new way to control pancreatic tumors and improve survival when used with standard chemotherapy.

What could go wrong

This is an early safety study with only 30 participants, so results may not apply to everyone. The procedure is invasive and side effects are unknown.

Conditions

The condition(s) this trial relates to.

pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.